Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov;42(11):4747-4749.
doi: 10.1007/s10072-021-05467-w. Epub 2021 Jul 17.

A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine

Nicola Alessandro Nasuelli  1 , Fabiola De Marchi  2   3 , Michela Cecchin  2 , Irene De Paoli  2 , Susanna Onorato  2 , Roberto Pettinaroli  2 , Giovanni Savoini  2 , Laura Godi  2
Affiliations
Case Reports

A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine

Nicola Alessandro Nasuelli et al. Neurol Sci. 2021 Nov.

Abstract

Background: The coronavirus disease 2019 (COVID-19) global pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began in late 2019. Researchers around the world are aggressively working to develop a vaccine. One of the vaccines approved against COVID-19 is Oxford-AstraZeneca chimpanzee adenovirus vectored vaccine ChAdOx1 nCoV-19.

Case report: We described a patient who developed four limb distal paraesthesia, postural instability, and facial diplegia, ten days after vaccination with ChAdOx1 nCoV-19 (ABW1277). The electrophysiological findings were compatible with acute demyelinating motor polyneuropathy (Guillain-Barrè syndrome).

Discussion: We therefore want to describe a temporal correlation between administration of ChAdOx1 nCoV-19 (ABW1277) vaccine and GBS without evidence of other predisposing infectious or autoimmune factors. This paper aims to highlight the importance of pharmacovigilance and subsequent reports will be needed to evaluate the possible correlation between these two events.

Keywords: COVID-19; Guillain-Barrè syndrome; Pandemic; Vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Tibial (a) and facial (b) nerve compound muscle action potential (cMAP), showing potential temporal dispersion
See this image and copyright information in PMC

References

    1. Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;14(11):585354. doi: 10.3389/fimmu.2020.585354. - DOI - PMC - PubMed
    1. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72–74. doi: 10.1016/S0140-6736(20)32623-4. - DOI - PMC - PubMed
    1. Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA, Mangat HS. Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine. Ann Neurol. 2021 doi: 10.1002/ana.26143. - DOI - PubMed
    1. Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, Evans JR. Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021 doi: 10.1002/ana.26144. - DOI - PubMed
    1. Donofrio PD. Guillain-Barré Syndrome. Continuum (Minneap Minn) 2017;23(5, Peripheral Nerve and Motor Neuron Disorders):1295–1309. doi: 10.1212/CON.0000000000000513. - DOI - PubMed

Publication types